Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting -

- Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) -

Read more at globenewswire.com